Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Other Accumulated Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Other Accumulated Expenses data on record, last reported at $35.4 million in Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 42.22% to $35.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $35.4 million, a 42.22% increase, with the full-year FY2025 number at $41.4 million, up 14.67% from a year prior.
  • Other Accumulated Expenses reached $35.4 million in Q1 2026 per OLMA's latest filing, down from $41.4 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for OLMA hit a ceiling of $41.4 million in Q4 2025 and a floor of $4.9 million in Q1 2022.
  • A 5-year average of $19.8 million and a median of $15.2 million in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 17127.27% in 2022, then dropped 26.93% in 2023.
  • Tracing OLMA's Other Accumulated Expenses over 5 years: stood at $15.2 million in 2022, then dropped by 25.32% to $11.3 million in 2023, then skyrocketed by 219.08% to $36.1 million in 2024, then increased by 14.67% to $41.4 million in 2025, then dropped by 14.55% to $35.4 million in 2026.
  • Business Quant data shows Other Accumulated Expenses for OLMA at $35.4 million in Q1 2026, $41.4 million in Q4 2025, and $29.7 million in Q3 2025.